Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Shrinking team NBB
FTE fell two years in a row, from 486.5 to 291.5.
-
Busy address KBO
51 other companies have their registered office at the same address; threshold 10.
Financials
Financial year 2024
Lakefront Biotherapeutics from Mechelen, company number BE0466460429, closed financial year 2024 with a result of € 47.8 million after tax. For that financial year Lakefront Biotherapeutics recorded revenue of € 303.4 million and equity of € 2.8 billion. Compared with financial year 2023, the result moved from € 271.3 million to € 47.8 million. The company is profitable. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on May 22, 2025.
€ 2.8 billion
▲ 2% vs 2023
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 47.8 million
▼ 82% vs 2023
Profit after tax over the fiscal year.
€ 60.1 million
▼ 13% vs 2023
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2024. Retained profit grew to € -188.1 million.
People and assets in 2024
291.5
▼ 77.1 vs 2023
Average over the fiscal year, from the social balance sheet.
€ 57.9 million
▼ 21% vs 2023
€ 198,500 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 992,909
▼ 19% vs 2023
Book value of vehicles, furniture and equipment.
Debts at end 2024
None
No bank loans on the last day of the fiscal year.
€ 92.5 million
▼ 28% vs 2023
Supplier invoices still open on the last day of the fiscal year. Pays suppliers within 89 days on average.
€ 12 million
▼ 50% vs 2023
Taxes, VAT and social contributions still to pay.
| 2021 | 2023 | 2024 | Change 2023 → 2024 | |
|---|---|---|---|---|
| Revenue | € 503,389,558 | € 628,899,063 | € 303,425,198 | ▼ 52% |
| Profit after taxes | € -92,737,426 | € 271,292,107 | € 47,781,908 | ▼ 82% |
| Equity | € 2,639,924,301 | € 2,781,701,891 | € 2,829,483,799 | ▲ 2% |
| Total debts | € 2,471,623,002 | € 1,505,587,142 | € 1,197,120,467 | ▼ 20% |
| Cash | € 1,203,980,495 | € 69,381,431 | € 60,140,851 | ▼ 13% |
| Land & buildings | € 2,642,252 | € 871,570 | € 354,535 | ▼ 59% |
| Retained profit | € -369,236,867 | € -235,924,484 | € -188,142,575 | ▲ € 47.8 million |
| Bank debt | € 652,249 | € 0 | € 0 | |
| Balance sheet total | € 5,120,432,736 | € 4,301,261,099 | € 4,044,144,044 | ▼ 6% |
| Employees (FTE) | 486.5 | 368.6 | 291.5 | ▼ 77.1 |
Key figures of Lakefront Biotherapeutics, fiscal years 2021 to 2024, from the annual accounts filed with the National Bank of Belgium.The annual account for fiscal year 2025 has not been filed yet; it was expected before 31 July 2026.
What happened to Lakefront Biotherapeutics?
What happened at Lakefront Biotherapeutics in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Andrew Dickinson stepped down as director. NBB
- Susanne Schaffert stepped down as director. NBB
- Elisabeth Svanberg stepped down as director. NBB
- Simon Sturge stepped down as director. NBB
- Linda Higgins stepped down as director. NBB
- Peter Guenter stepped down as director. NBB
- Oleg Nodelman stepped down as director. NBB
- Stoffels IMC BV stepped down as director. NBB
In short
From € 92.7 million loss in 2021 to € 47.8 million profit in 2024.
Best year ever: 2023, with € 271.3 million profit.
Pays suppliers within 89 days on average.
Management
It owns 100% of Galapagos U.K. ltd, 100% of Galapagos Holding Pte Ltd, 100% of Galapagos Real Estate Belgium, 100% of Galapagos US Holding Inc, 100% of Galapagos GmbH and 100% of Galapagos Real Estate Netherlands B.V. itself.
Directors
According to the 2024 annual accounts
Oleg Nodelman
Director
since 2024 · until 2026
Linda Higgins
Director
since 2023 · until 2027
Chairman of the board · represented by Paul Stoffels
since 2022 · until 2026
Peter Guenter
Director
since 2023 · until 2027
Susanne Schaffert
Director
since 2023 · until 2028
Elisabeth Svanberg
Director
since 2024 · until 2028
Jérôme Contamine
Director
since 2022 · until 2026
Simon Sturge
Director
since 2023 · until 2028
Andrew Dickinson
Director
since 2024 · until 2028
Establishments
Establishment units
Physical locations of this company
Schaliënhoevedreef 20T
2800 Mechelen
Generaal De Wittelaan 11
2800 Mechelen
Active since 19 August 1999
Schaliënhoevedreef 20 box T
2800 Mechelen
Active since 1 January 2018
Generaal De Wittelaan 21
2800 Mechelen
Active since 1 January 2018
Schaliënhoevedreef 20 box F
2800 Mechelen
Active since 22 January 2020
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 51 companies are registered at this address.
All companies at this address →FINAL TOUCH
Hal Leonard Europe
€ 220,326 gross margin · 2025
Whiterock
€ -5,199 gross margin · 2025
ASTERION BELGIUM
€ 3.3 million revenue · 2024
Curium Belgium
€ 7.8 million revenue · 2025
+46 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0466.460.429
- VAT number
- BE 0466.460.429
- Registered office
- Schaliënhoevedreef 20T, 2800 Mechelen
- Names & denominations
- Lakefront Biotherapeutics
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 6 July 1999
- Peppol
- Active · Active since 11 Dec 2025
- Activities · NACE
Speur- en ontwikkelingswerk op natuurwetenschappelijk gebied
Speur- en ontwikkelingswerk op biotechnologisch gebied
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied